Moderna (MRNA) Resumen de Acciones
Moderna, Inc, empresa de biotecnología, suministra medicamentos de ARN mensajero en Estados Unidos, Europa y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en MRNA a partir de nuestros controles de riesgos.
MRNA Community Fair Values
Create NarrativeSee what 258 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$175
FV
64.0% infravalorado descuento intrínseco993
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
25users have followed this narrative
Competidores de Moderna, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$62.96 |
| Máximo en las últimas 52 semanas | US$85.60 |
| Mínimo de 52 semanas | US$22.28 |
| Beta | 0.90 |
| Cambio en 1 mes | 1.84% |
| Variación en 3 meses | 30.84% |
| Cambio de 1 año | 125.58% |
| Variación en 3 años | -45.84% |
| Variación en 5 años | -84.06% |
| Variación desde la OPV | 238.49% |
Noticias y actualizaciones recientes
Actualización de narrativa • Aug 10
MRNA: Future Upside Will Hinge On New Flu Vaccine Rollout
Analysts have lifted their fair value estimate for Moderna stock from about $66.29 to roughly $78.89. This reflects updated models that incorporate higher assumed revenue growth, a slightly higher discount rate, modestly lower profit margin expectations, and a higher future P/E multiple in line with recent increases in Street price targets across major research firms.Seeking Alpha • Aug 10
Moderna: I'm Still On Sell, But Here's What Would Change My Mind
Summary Moderna faces valuation challenges, requiring near-perfect execution and rapid margin expansion across its late-stage assets to justify its $20B+ market cap. Q2 revenue was $145M with a net loss of $782M; management targets 10% Y/Y revenue growth and $4.7–$5.2B year-end cash/investments. mFLUSIVA's FDA approval is a milestone, but $1B peak sales is a best-case scenario given entrenched competitors and tepid mRNA vaccine adoption post-COVID. MRNA's pipeline setbacks include slow norovirus trial enrollment and underwhelming mRESVIA sales, while oncology and rare disease assets must deliver $5B by 2034 to support valuation. Read the full article on Seeking AlphaRecent updates
Actualización de narrativa • Aug 10
MRNA: Future Upside Will Hinge On New Flu Vaccine Rollout
Analysts have lifted their fair value estimate for Moderna stock from about $66.29 to roughly $78.89. This reflects updated models that incorporate higher assumed revenue growth, a slightly higher discount rate, modestly lower profit margin expectations, and a higher future P/E multiple in line with recent increases in Street price targets across major research firms.Seeking Alpha • Aug 10
Moderna: I'm Still On Sell, But Here's What Would Change My Mind
Summary Moderna faces valuation challenges, requiring near-perfect execution and rapid margin expansion across its late-stage assets to justify its $20B+ market cap. Q2 revenue was $145M with a net loss of $782M; management targets 10% Y/Y revenue growth and $4.7–$5.2B year-end cash/investments. mFLUSIVA's FDA approval is a milestone, but $1B peak sales is a best-case scenario given entrenched competitors and tepid mRNA vaccine adoption post-COVID. MRNA's pipeline setbacks include slow norovirus trial enrollment and underwhelming mRESVIA sales, while oncology and rare disease assets must deliver $5B by 2034 to support valuation. Read the full article on Seeking Alpha
Actualización de narrativa • Jul 27
MRNA: Flu Revenue Delays And Regulatory Timing Will Constrain Future Upside
Analysts have lifted their fair value estimate for Moderna stock from $22.00 to $25.00, reflecting updated assumptions around revenue growth, profitability, and future P/E multiples in light of a series of higher Street price targets and supportive commentary on the company's vaccine pipeline. Analyst Commentary Recent research coverage of Moderna shows a mix of optimism around the vaccine portfolio and caution around execution, timing of revenues, and valuation.Actualización de narrativa • Jul 13
MRNA: Flu Approval Uncertainty And Delayed Vaccine Revenues Will Restrain Upside
Analysts have nudged their fair value estimate for Moderna to $22.00, citing a series of recently higher Street price targets that reflect increased attention on upcoming vaccine catalysts, sector momentum, and company specific earnings drivers. Analyst Commentary Street research on Moderna reflects a mix of optimism around the vaccine pipeline and caution around execution, earnings visibility, and valuation.
Actualización de narrativa • Jun 29
MRNA: Flu Approval Progress Will Still Limit Long Term Upside
Moderna's updated analyst price target framework reflects a modest fair value adjustment to about $44.25 per share, along with higher modeled revenue growth and profit margins and a lower future P/E multiple, as analysts factor in supportive regulatory commentary on the mRNA flu program and incremental optimism around the broader vaccine pipeline. Analyst Commentary Recent Street research around Moderna highlights a mix of optimism tied to the mRNA flu and broader vaccine pipeline, and caution around timing, clinical data gaps, and execution risk.Artículo de análisis • Jun 21
Moderna (MRNA) Stock Could Be 39% Overvalued After FDA Flu Vaccine Backing
Moderna (MRNA) is back in focus after a unanimous FDA advisory panel vote that its investigational mRNA flu vaccine, mFlusiva, has a favorable benefit risk profile in adults 50 and older. See our latest analysis for Moderna. Moderna’s recent regulatory win has arrived after a sharp rebound in the stock, with a 1-year total shareholder return of 146.95% and a year to date share price return of 107.26%, while the 3 and 5 year total shareholder returns remain significantly lower. This suggests...Actualización de narrativa • Jun 15
MRNA: Flu Review And Pipeline Execution Risk Are Expected To Restrain Upside
Moderna's updated analyst price target edges higher, with the model fair value moving from $21.00 to about $21.09 as analysts factor in slightly stronger revenue growth expectations and potential upside from norovirus vaccine penetration. Analyst Commentary Recent Street research on Moderna clusters around cautious optimism, with several firms adjusting price targets while still highlighting meaningful risks tied to execution and future growth drivers, especially in vaccines beyond Covid.Actualización de narrativa • Jun 01
MRNA: Flu Review And Litigation Overhang Will Continue To Restrain Upside
Analysts raised Moderna’s fair value estimate from $12.00 to $21.00, citing a series of higher Street price targets and updated assumptions for margins, litigation risk, and future P/E multiples. Analyst Commentary Recent Street research around Moderna has centered on two themes: valuation reset after the litigation settlement and differing views on how much residual legal and execution risk still matters for the stock.Actualización de narrativa • May 13
MRNA: Future Upside Will Depend On Upcoming Flu Vaccine Authorization Outcome
Narrative Update on Moderna Analysts have collectively raised their Moderna price targets by low to mid single digit dollar amounts, citing updated models that reflect recent litigation settlements, FDA progress on the flu vaccine, and oncology pipeline developments. Together, these factors support a lower fair value estimate of $66.29, a slightly higher discount rate of 7.21%, adjusted revenue growth expectations of 52.59%, a profit margin of 4.12%, and a future P/E assumption of 107.40x.Actualización de narrativa • Apr 27
MRNA: Litigation Tail And Uncertain Flu Path Will Limit Long-Term Upside
Analysts have lifted the implied fair value estimate for Moderna shares by about $7, citing a reset in litigation risk following the Arbutus and Genevant settlement and refreshed expectations for the flu and broader vaccine pipeline that flow through to higher modeled revenue growth and a richer future P/E multiple. Analyst Commentary Street research on Moderna has been active, with several firms revisiting their models after the Arbutus and Genevant settlement, the Q4 earnings update, and the FDA's decision to review the mRNA-1010 flu vaccine.Actualización de narrativa • Apr 13
MRNA: Flu Review Uncertainty And Legal Tail Risk Will Constrain Upside
Analysts have nudged Moderna's average price target higher by $5, reflecting a mix of renewed confidence in the company's vaccine pipeline after the FDA's reconsideration of its flu shot application and reduced litigation overhang following recent settlement developments. Analyst Commentary Recent research on Moderna clusters around two main themes for you to watch closely: valuation reset around the vaccine pipeline and lingering legal and execution risks tied to the COVID and flu franchises.Actualización de narrativa • Mar 30
MRNA: Litigation Deal And Flu Review Path Will Limit Future Upside
Analyst price targets for Moderna have generally shifted higher, with several firms moving into a $30 to $69 range as they factor in the recent Arbutus settlement, the FDA’s renewed review of the mRNA-1010 flu vaccine with an August 5 PDUFA date, and updated product and oncology pipeline assumptions. Analyst Commentary Street research on Moderna currently reflects a mixed but generally cautious stance, even as litigation and regulatory headlines have reduced some overhangs.Actualización de narrativa • Mar 16
MRNA: Litigation Settlement And Flu Setback Will Constrain Future Upside
Analysts have trimmed Moderna's implied fair value from $15.00 to $12.00 as they factor in a higher discount rate, more moderate profit margins and updated views on revenue growth following recent litigation settlements and regulatory updates. Analyst Commentary Street research around Moderna centers on two themes that matter for you as an investor: the clean-up of legal overhangs and how much confidence to place in the broader vaccine and oncology pipeline.Actualización de narrativa • Mar 02
MRNA: Future Upside Will Hinge On Upcoming Flu Vaccine Approval Decision
Our fair value estimate for Moderna has inched up by about $1.65 per share to $91.97 as analysts update their models around higher projected product sales, a more constructive FDA review path for the mRNA-1010 flu vaccine with an August 5 PDUFA date, and refreshed views on the broader late stage pipeline including oncology. Analyst Commentary Street research on Moderna has leaned more constructive around the updated regulatory path for flu vaccine mRNA-1010, the broader late stage pipeline, and recent quarterly disclosures.Artículo de análisis • Feb 17
Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90
As you might know, Moderna, Inc. ( NASDAQ:MRNA ) just kicked off its latest annual results with some very strong...Actualización de narrativa • Feb 16
MRNA: Future Upside Will Depend On Vaccine Pipeline Execution Outcomes
Analysts have nudged their average price target for Moderna higher by about $3, reflecting updated views on long term revenue potential, profit margins and a higher future P/E multiple following recent research on COVID demand, the broader vaccine pipeline and legal outcomes. Analyst Commentary Recent Street research on Moderna highlights a mix of caution and growing optimism, with several bullish analysts adjusting their models after company updates, legal developments and new financing disclosures.Artículo de análisis • Feb 02
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Despite an already strong run, Moderna, Inc. ( NASDAQ:MRNA ) shares have been powering on, with a gain of 43% in the...Actualización de narrativa • Feb 01
MRNA: Cancer Vaccine Risk And Vaccine Backlash Will Restrain Long-Term Upside
The analyst price target for Moderna has increased by about $2 to $38.80, as analysts incorporate updated assumptions for slightly stronger revenue growth, modestly better profit margins, a marginally lower discount rate, and a slightly reduced future P/E multiple. Analyst Commentary Recent Street research on Moderna shows a mix of cautious optimism and ongoing concern.Actualización de narrativa • Jan 18
MRNA: Late Stage Vaccine Outcomes Will Define Future Upside Potential
Narrative update We trim our analyst price target for Moderna from about US$121 to roughly US$87 as analysts factor in lower profit margin expectations, a higher discount rate, cautious views on COVID-related revenue visibility, and a more binary risk profile around key late stage vaccine data, even as some models reflect higher revenue growth assumptions and updated financing terms. Analyst Commentary Recent Street research on Moderna points to a mixed backdrop, with several firms reaffirming cautious stances while still recognizing specific areas where execution and funding choices could support long term value creation.Actualización de narrativa • Jan 04
MRNA: Oncology Progress Will Drive Long-Term Upside Despite Debt And Litigation
Analysts have modestly lifted their price targets on Moderna, with recent revisions such as $15 to $18, $16 to $17, and $32 to $30. These changes collectively reflect slightly improved conviction in the company’s long term revenue growth, gross margin expansion, and strengthened liquidity following new Ares financing, despite ongoing profitability and litigation risks.Actualización de narrativa • Dec 21
MRNA: Oncology Advances And Buyout Optionality Will Offset Debt And Litigation Risks
Analysts have modestly raised their price target on Moderna to align with a slightly higher fair value estimate of about $36.75, citing incremental improvements in long term revenue growth and profitability assumptions supported by recent Investor and Analyst Day updates, revised 2026 to 2028 guidance, and Ares financing. Analyst Commentary Recent Street research reflects a cautious but incrementally more constructive stance toward Moderna, with several firms refining their models following Investor and Analyst Day presentations and the announcement of new financing.Artículo de análisis • Dec 19
There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise
Moderna, Inc. ( NASDAQ:MRNA ) shareholders have had their patience rewarded with a 28% share price jump in the last...Actualización de narrativa • Dec 07
MRNA: Oncology Pipeline Progress Will Drive Long Term Upside Despite Litigation Risk
Analysts have modestly lowered their price target on Moderna to about $35.78 from $37.32 per share, reflecting slightly softer long term growth and valuation assumptions. This comes even as recent Investor and Analyst Day updates, new debt financing and evolving oncology data support a more stable cash outlook and gradual margin improvement.Actualización de narrativa • Nov 23
MRNA: Oncology Pipeline Advances Will Drive Renewed Optimism Despite Regulatory Shifts
Analysts have revised their fair value estimate for Moderna down from approximately $40.30 to $37.32. They cited the company’s updated revenue growth projections and cost outlook, despite improvements in profit margins and continued progress across its commercial and research pipelines.Actualización de narrativa • Nov 07
MRNA: Oncology Progress Will Drive Renewed Optimism Amid Regulatory Uncertainties
Moderna's analyst price target was reduced from $18 to $15, as analysts pointed to lower US vaccination trends and ongoing regulatory uncertainties that are impacting the outlook for its vaccine franchises. Analyst Commentary Recent analyst notes have reflected both cautious and optimistic perspectives on Moderna's outlook.Actualización de narrativa • Oct 23
Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts
Moderna’s analyst price target has been revised downward from $44.25 to $40.30. Analysts cite lower projected revenue growth along with persistent regulatory and profitability challenges, which have been reflected in recent industry commentary.Actualización de narrativa • Sep 04
Pipeline Diversification And Regulatory Momentum Will Unlock Future Potential
Moderna’s consensus price target was held at $44.25 as analysts cited declining US vaccine demand, increased regulatory hurdles for flu/COVID combinations, delayed UK deliveries impacting 2025 guidance, and persistent uncertainty around mRNA vaccine approvals. Analyst Commentary Lowered US vaccination trends for both COVID and flu are reducing addressable market expectations for Moderna’s vaccines.Nueva narrativa • May 02
MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK
Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing andSeeking Alpha • Apr 22
More Downside For Moderna Before The Breakthrough
Summary Moderna's respiratory vaccine sales are not encouraging, and competition is strong, making it difficult to gain market share and sustain revenue. The product pipeline is promising but requires investor patience, with key vaccines in Phase 3 trials but regulatory approvals potentially years away. Financials are sound enough to support long term research, with a significant cash buffer, but oncology research faces regulatory and technical challenges. Shares are likely to go down before any uptrend (2-3 years horizon). Read the full article on Seeking AlphaSeeking Alpha • Mar 31
FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade)
Summary Moderna's stock dropped over 10% after the FDA's Dr. Peter Marks resigned, signaling potential increased regulatory scrutiny on vaccines. Moderna's financial health remains strong, with ~$9 billion in cash and investments, but the stock is down 65% since my August rating downgrade. Despite pipeline progress, regulatory uncertainty and intense competition from Pfizer and GSK pose significant risks to Moderna's revenue outlook. Given the negative public perception of mRNA technology and regulatory risks, I downgrade MRNA to "Hold" until more clarity emerges. Read the full article on Seeking AlphaSeeking Alpha • Mar 06
Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out
Summary Moderna, Inc.'s stock surged 16% yesterday after a German court ruled Pfizer and BioNTech may have violated Moderna's COVID-19 vaccine patent, potentially leading to compensation. Despite the ruling, Pfizer and BioNTech will appeal, while previous court decisions have invalidated related patents, complicating Moderna's legal victory. MRNA's business struggles post-pandemic, with declining revenues and few new products, have made litigation a potentially critical revenue source, which I'd call a red flag. The ongoing legal battles resemble other prolonged patent disputes, highlighting the challenges in monetizing groundbreaking technologies like mRNA and CRISPR. If Moderna had released ten products since 2022, instead of one, it's unlikely yesterday's news would have moved its share price, but this reflects the new reality of messenger-RNA, a technology that hasn't lived up to the hype — yet. Read the full article on Seeking AlphaSeeking Alpha • Feb 14
Moderna, Inc.: Working Hard But Competition Is Working Harder
Summary MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition. Despite negative financials, technical analysis indicates potential support at $28-30, justifying a "hold" position rather than a "sell.". Read the full article on Seeking Alpha
Nueva narrativa • Feb 09
Vaccine Expansion Plans Could Shape Future Despite Market Challenges And Legal Risks
Strategic product innovation in combining vaccines could enhance long-term revenue streams and international market positioning.Seeking Alpha • Feb 03
Moderna: The Good News Isn't Enough
Summary I initially rated Moderna as a SELL in mid-December, and despite a recent rally, the stock remains volatile. The news flow has been great in January, which mostly caused a rally in the stock. I argue why I don't think anything has changed materially, reinforcing my SELL rating. Despite cost-cutting measures, I am concerned that reducing R&D will hurt Moderna's research capabilities, preferring cuts in SG&A instead. Read the full article on Seeking AlphaRentabilidad de los accionistas
| MRNA | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 3.9% | 1.8% | -0.3% |
| 1Y | 125.6% | 40.4% | 19.9% |
Rentabilidad vs. Industria: MRNA superó a la industria US Biotechs, que obtuvo un rendimiento del 40.4% el año pasado.
Rentabilidad vs. Mercado: MRNA superó al mercado US, que obtuvo un rendimiento del 19.9% el año pasado.
Volatilidad de los precios
| MRNA volatility | |
|---|---|
| MRNA Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: MRNA no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MRNA (11%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2010 | 4,700 | Stéphane Bancel | www.modernatx.com |
Moderna, Inc, empresa de biotecnología, suministra medicamentos de ARN mensajero en Estados Unidos, Europa y a escala internacional. Las vacunas respiratorias de la empresa incluyen spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, la vacuna contra la gripe estacional, la vacuna combinada y la vacuna contra la gripe pandémica; las vacunas latentes comprenden las vacunas contra el citomegalovirus, el virus de Epstein-Barr y el virus de la inmunodeficiencia humana; los virus entéricos incluyen el norovirus; las vacunas de salud pública consisten en las vacunas contra el Zika, Nipah y Mpox; y las vacunas contra enfermedades bacterianas, como las vacunas contra el lyme. También ofrece productos terapéuticos oncológicos, como el autogen intismeran, la terapia antigénica del cáncer, el activador de células t y el potenciador de terapia celular; y productos para enfermedades raras, como la acidemia propiónica y metilmalónica, y la fibrosis quística.
Resumen de fundamentos de Moderna, Inc.
| Estadísticas fundamentales de MRNA | |
|---|---|
| Capitalización bursátil | US$25.73b |
| Beneficios(TTM) | -US$3.15b |
| Ingresos (TTM) | US$2.23b |
11.3x
Ratio precio-ventas (PS)-8.0x
Ratio precio-beneficio (PE)¿Está MRNA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MRNA | |
|---|---|
| Ingresos | US$2.23b |
| Coste de los ingresos | US$3.70b |
| Beneficio bruto | -US$1.47b |
| Otros gastos | US$1.68b |
| Beneficios | -US$3.15b |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -7.89 |
| Margen bruto | -66.02% |
| Margen de beneficio neto | -141.43% |
| Ratio deuda/patrimonio | 8.7% |
¿Cómo se ha desempeñado MRNA a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/18 06:43 |
| Precio de las acciones al final del día | 2026/08/18 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Moderna, Inc. está cubierta por 42 analistas. 21 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | Argus Research Company |
| Eliana Merle | Barclays |
| Huidong Wang | Barclays |